Henry Schein (HSIC) 44th Annual J.P. Morgan Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
44th Annual J.P. Morgan Healthcare Conference summary
17 Nov, 2026Leadership transition and profile
Fred Lowery, currently EVP and President of Laboratory Products and BioProduction at Thermo Fisher Scientific, was named CEO effective March 2; he brings 20+ years of healthcare experience and a record of scaling complex businesses.
Succession considered internal and external candidates, with an orderly transition as a priority.
Leadership and the board expressed confidence in Lowery’s fit to advance BOLD+1 and value creation; culture and values remain differentiators, with momentum strong after the cyber incident.
Operating performance and market outlook
2025 sales growth accelerated across reportable segments, with stable dental conditions, steady medical patient traffic and market-share gains across most businesses; Specialty Products and Technology benefited from new offerings, while Distribution gained share.
Dental conditions were stable to slightly positive, with pricing pressure as purchasing shifted from national brands to private labels.
Growth drivers include share gains, a broad portfolio, omnichannel execution and increased sales-force investment; mid-market and large DSOs are growing faster than independent practices.
Financial highlights and value creation
A $200M+ operating-income improvement plan targets lower global SG&A and higher gross margins; net benefits are expected in 2026, with full impact by 2027.
BOLD+1 targets 60% of operating income from high-growth, high-margin and owned-brand products by 2027; the plan also specifies over 50% of non-GAAP operating income from high-growth, high-margin businesses plus more than 10% from corporate brands.
Strong cash flow supported strategic investment, including accelerated share repurchases; buybacks were described as accretive to EPS.
From 2017–2024, non-GAAP operating income CAGR was 3.6% and non-GAAP diluted EPS CAGR was 6.2%; the 2023 cyber incident was estimated to reduce operating income by $120M–$130M and EPS by $0.70–$0.75.
Latest events from Henry Schein
- Technology, mix shift and productivity underpin growth and value-creation targets.HSIC
Jefferies Global Healthcare Conference - FY2025 sales grew 4%, with a 2027 target to source over half of non-GAAP operating income from high-growth businesses.HSIC
Corporate presentation - Q3 sales rose 4%, adjusted EPS grew 19.1%, and FY2026 EPS guidance increased.HSIC
Q3 2026 - Growth acceleration, operational rigor, and disciplined capital allocation drive strong performance.HSIC
2026 Global Healthcare Conference - Global leader in dental and medical products with $13.2B sales and strong growth momentum.HSIC
Corporate presentation - Q2 2026 saw strong sales, margin gains, and raised guidance, with robust segment growth.HSIC
Q2 2026 - Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 2025 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 2024 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 2024